

Ihosvany Fernandez Bello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1351997/publications.pdf>

Version: 2024-02-01

32
papers

350
citations

758635

12
h-index

794141

19
g-index

32
all docs

32
docs citations

32
times ranked

577
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. Archivos De Bronconeumologia, 2022, 58, 117-124. | 0.4 | 20 |
| 2 | Monitoring of new therapies for hemophilia. Blood Coagulation and Fibrinolysis, 2022, 33, S3-S4. | 0.5 | 0 |
| 3 | Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience. Haemophilia, 2020, 26, e247-e249. | 1.0 | 5 |
| 4 | Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation. British Journal of Haematology, 2020, 189, 943-953. | 1.2 | 27 |
| 5 | Thrombin Generation Related to Netosis in Patients with Systemic Lupus Erythematosus. Blood, 2020, 136, 10-11. | 0.6 | 1 |
| 6 | The in Vitro procoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. Blood, 2020, 136, 18-19. | 0.6 | 0 |
| 7 | Fibrin Polymerization Ability Influences Joint Condition in Patients with Severe Haemophilia. Blood, 2020, 136, 17-18. | 0.6 | 0 |
| 8 | Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. Thrombosis and Haemostasis, 2019, 119, 645-659. | 1.8 | 31 |
| 9 | Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein. Blood, 2019, 134, 4929-4929. | 0.6 | 2 |
| 10 | Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus. Blood, 2019, 134, 1141-1141. | 0.6 | 1 |
| 11 | Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments. Blood, 2019, 134, 1089-1089. | 0.6 | 1 |
| 12 | Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. Blood, 2019, 134, 1118-1118. | 0.6 | 0 |
| 13 | Immune thrombocytopenia "in defence of the platelet count. Response to Hill. British Journal of Haematology, 2018, 182, 130-131. | 1.2 | 0 |
| 14 | Platelet Protein Glycosylation in Immune Thrombocytopenia. Blood, 2018, 132, 2437-2437. | 0.6 | 2 |
| 15 | Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. Blood, 2018, 132, 5048-5048. | 0.6 | 0 |
| 16 | Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT [®] in patients with severe haemophilia A without inhibitors. Haemophilia, 2017, 23, e50-e54. | 1.0 | 35 |
| 17 | The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. Haemophilia, 2017, 23, 868-876. | 1.0 | 14 |
| 18 | Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. Aids, 2016, 30, 1141-1142. | 1.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Procoagulant profile in patients with immune thrombocytopenia. British Journal of Haematology, 2016, 175, 925-934. | 1.2 | 42 |
| 20 | Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 621-628. | 1.5 | 29 |
| 21 | Effect of thrombopoietin receptor agonists on a proliferation-inducing ligand (<scp>APRIL</scp>) plasma levels in patients with immune thrombocytopenia. British Journal of Clinical Pharmacology, 2014, 78, 674-676. | 1.1 | 4 |
| 22 | Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thrombosis and Haemostasis, 2014, 112, 65-72. | 1.8 | 28 |
| 23 | Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin. Blood, 2014, 124, 1462-1462. | 0.6 | 0 |
| 24 | Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. Orphanet Journal of Rare Diseases, 2013, 8, 81. | 1.2 | 20 |
| 25 | Rotational thromboelastometry (ROTEM) in Behçet's disease. Clinical Rheumatology, 2013, 32, 1691-1691. | 1.0 | 0 |
| 26 | Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. Thrombosis and Haemostasis, 2013, 109, 909-919. | 1.8 | 13 |
| 27 | Procoagulant Status In Patients With Immune Thrombocytopenia. Blood, 2013, 122, 3528-3528. | 0.6 | 1 |
| 28 | Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia. Blood, 2013, 122, 1083-1083. | 0.6 | 0 |
| 29 | Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. Thrombosis and Haemostasis, 2012, 107, 88-98. | 1.8 | 25 |
| 30 | Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center. Blood, 2012, 120, 4658-4658. | 0.6 | 0 |
| 31 | Clinical and genetic findings in five female patients with haemophilia A: Identification of a novel missense mutation, p.Phe2127Ser. Thrombosis and Haemostasis, 2010, 104, 718-723. | 1.8 | 15 |
| 32 | Controversies and Challenges in Elective Orthopedic Surgery in Patients With Hemophilia and Inhibitors. Seminars in Hematology, 2008, 45, S64-S67. | 1.8 | 27 |